Please sign in to follow a disease.
Essential thrombocythemia
MONDO:0005029A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008)
Also known as: ET, essential thrombocytemia, essential thrombocythemia, essential thrombocytosis, primary thrombocythemia, primary thrombocytosis, idiopathic thrombocythemia
3113 clinical trials for this condition and its sub-types, 67 tagged with Essential thrombocythemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Experimental combo for rare blood cancer shows promise but trial halted early
Disease control Stopped earlyThis early-phase trial tested a combination of two drugs—ruxolitinib and CPX-351—in 12 people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The goal was to find the best dose and see if the combo could shrink cancer. However, the study was stop…
Phase 1/2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for blood cancer patients: drug shows promise in controlling disease
Disease control Stopped earlyThis study tested a drug called ruxolitinib in 73 people with two types of blood cancer—polycythemia vera or essential thrombocythemia—that were not helped by standard treatment. The goal was to see if the drug could safely reduce high blood cell counts and symptoms like an enlar…
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC